Endo International (NASDAQ:ENDP) (TSE:ENL) has been assigned a $7.00 target price by analysts at Cantor Fitzgerald in a note issued to investors on Tuesday. The firm currently has a “hold” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 2.34% from the stock’s current price.
The analysts wrote, “Takeaways from the quarter: 1) Executing well against its stated objectives in U.S. generics, during 4Q17, the U.S. generics segment launched six products and submitted two regulatory filings. In 2017, the U.S. generics segment launched 17 products and ENDP made 12 regulatory submissions. As of 12/31/17, ENDP had ~100 ANDAs (~1/3 FTF/FTM) pending with the FDA. 2) Sterile Injectables is a growing franchise. Sterile Injectables revenue increased 16% YOY. This increase was driven by Adrenalin. 3) Important sterile injectable drugs include Vasostrict and Adrenalin. ENDP reported 2017 Vasostrict sales of $400MM and Adrenalin sales of $77MM. 4) As of 12/31/17, ENDP had $987MM in unrestricted cash, net debt of ~$7.3B and a net leverage ratio of 4.6x. 5) 4Q17 cash provided by operating activities was $132MM, compared to $84MM of net cash provided by operating activities in 2016. 6) Cellulite could be a big opportunity for ENDP. RELEASE-1 And RELEASE-2 Phase 3 trials looking at Xiaflex for the treatment cellulite were initiated. Topline data are expected 1Q19. ENDP plans to submit all the data in 2019. ENDP expects to commercialize the product on its own, but would consider strategic alternatives. 7) ENDP thinks that the generic market seems more stable, but it is still early in 2018.””
A number of other equities analysts have also weighed in on the company. JMP Securities lowered Endo International from an “outperform” rating to a “market perform” rating in a research report on Monday. Barclays decreased their price target on Endo International from $15.00 to $10.00 and set an “equal weight” rating for the company in a report on Friday. Canaccord Genuity set a $7.00 price target on Endo International and gave the stock a “hold” rating in a report on Wednesday, February 21st. B. Riley initiated coverage on Endo International in a report on Wednesday, February 14th. They set a “buy” rating and a $10.00 price target for the company. Finally, ValuEngine downgraded Endo International from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Endo International currently has a consensus rating of “Hold” and a consensus price target of $10.32.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Tuesday, February 27th. The company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.15. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The company had revenue of $768.64 million for the quarter, compared to analyst estimates of $762.29 million. During the same period in the prior year, the firm earned $1.77 earnings per share. Endo International’s revenue for the quarter was down 38.1% on a year-over-year basis. research analysts anticipate that Endo International will post 3.67 EPS for the current year.
A number of large investors have recently made changes to their positions in the business. UBS Asset Management Americas Inc. grew its stake in Endo International by 4.4% in the 4th quarter. UBS Asset Management Americas Inc. now owns 221,992 shares of the company’s stock valued at $1,720,000 after purchasing an additional 9,438 shares during the period. Paloma Partners Management Co bought a new position in Endo International in the 4th quarter valued at $122,000. Oakbrook Investments LLC bought a new position in Endo International in the 4th quarter valued at $133,000. LMR Partners LLP bought a new position in Endo International in the 3rd quarter valued at $148,000. Finally, Xact Kapitalforvaltning AB bought a new position in Endo International in the 4th quarter valued at $157,000. Hedge funds and other institutional investors own 92.54% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3226118/endo-international-endp-pt-set-at-7-00-by-cantor-fitzgerald.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.